Loading…
Definium Therapeutics, Inc. is projected to rise to $62.75 by 2027, a +41% move from its current price of $44.49. DFTX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $43.04 | $44.52 | $46.05 | +0.06% |
| Aug 2 | $42.46 | $44.54 | $46.72 | +0.12% |
| Aug 3 | $42.03 | $44.57 | $47.26 | +0.17% |
| Aug 4 | $41.68 | $44.59 | $47.71 | +0.23% |
| Aug 5 | $41.37 | $44.62 | $48.12 | +0.29% |
| Aug 6 | $41.10 | $44.65 | $48.50 | +0.35% |
| Aug 7 | $40.85 | $44.67 | $48.85 | +0.41% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $40.85 | $44.67 | $48.85 | +0.41% |
| Week 2 | $39.52 | $44.85 | $50.90 | +0.82% |
| Week 3 | $38.57 | $45.04 | $52.59 | +1.23% |
| Week 4 | $37.81 | $45.22 | $54.08 | +1.64% |
| Week 5 | $37.17 | $45.40 | $55.46 | +2.05% |
| Week 6 | $36.61 | $45.59 | $56.76 | +2.47% |
| Week 7 | $36.12 | $45.77 | $58.00 | +2.88% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Definium Therapeutics, Inc. is a clinical biopharmaceutical company in the Healthcare sector that develops novel product candidates to treat brain health disorders. Its lead product candidates include DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders, and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder.
The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
Definium Therapeutics, Inc. trades at $42.80, with a market cap of $5.68B, and is ranked 1207. The current price and market position place it among mid-cap healthcare names with a notable development pipeline in brain health disorders.
Forecasts show a neutral stance for 2026, with an average price of $42.80 and a range from $13.51 to $63.80, yielding an ROI of 0. The longer horizon displays a bullish trajectory from 2027 onward, with rising averages and increasingly strong ROIs through 2050, signaling substantial upside potential if the forecasts materialize.
From 2027 onward, the forecast projects bullish sentiment with rising annual averages: 2027 avg $61.38, 2028 avg $64.30, 2029 avg $74.89, 2030 avg $79.92, 2031 avg $88.52, 2032 avg $109.06, 2033 avg $132.60, 2034 avg $160.44, 2035 avg $174.93, 2040 avg $276.27, and 2050 avg $581.33. Max forecasts rise to $125.83 (2030), $526.84 (2040), and $1,239.20 (2050), with ROIs climbing to 86.7, 545.5, and 1258.2 respectively.
A major floor 66.1% below — a decisive break under it would weaken the trend.
The nearest floor, 45.1% below — buyers have tended to step in here.
The nearest ceiling, 8.9% above — a clean break opens room to run.
A major ceiling 41.9% above — clearing it would confirm fresh momentum.
Key DFTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DFTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $42.89 | Buy | $43.23 | Buy |
| MA 10 | $43.32 | Buy | $43.37 | Buy |
| MA 20 | $44.32 | Buy | $42.54 | Buy |
| MA 50 | $34.84 | Buy | $36.86 | Buy |
| MA 100 | $27.73 | Buy | $30.44 | Buy |
| MA 200 | $20.95 | Buy | $23.75 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 59.70 | Neutral |
| Stoch RSI (14) | 44.36 | Neutral |
| CCI (20) | 9.39 | Neutral |
| Williams %R (14) | -37.06 | Info |
| MACD (12,26,9) | -0.90 | Sell |
| ROC (12) | -3.24 | Sell |
| Bollinger %B (20,2) | 0.53 | Neutral |
| Stochastic %K (14) | 62.94 | Neutral |
| TRIX (15) | 1.13 | Buy |
| Awesome (5,34) | 2.48 | Buy |
| Ultimate (7,14,28) | 47.95 | Neutral |
| Momentum (10) | 0.39 | Buy |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 42.47 | Buy |
| ADX (14) | 27.47 | Buy |
| ATR (14) | 1.28 | Info |
The short-term technical picture sees bullish momentum with RSI(14) at 60, suggesting solid but not overbought momentum. The 50-day simple moving average sits at $31.37, while the 200-day simple moving average is at $19.71, indicating a constructive longer-term trend.
Key support and resistance levels are $22.95 and $48.45, respectively. The 30-day price range spans from $33.19 to $55.19, capturing a relatively wide near-term movement window for DF TX.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $13.51 | $44.49 | $63.55 | 0% | Neutral | |
| $48.95 | $62.75 | $85.67 | +41% | Bullish | |
| $50.99 | $67.75 | $96.77 | +52% | Bullish | |
| $56.30 | $77.07 | $113.98 | +73% | Bullish | |
| $59.87 | $84.15 | $128.12 | +89% | Bullish | |
| $66.16 | $95.27 | $148.75 | +114% | Bullish | |
| $77.35 | $113.94 | $181.95 | +156% | Bullish | |
| $92.76 | $139.59 | $227.48 | +214% | Bullish | |
| $109.04 | $167.46 | $278.02 | +276% | Bullish | |
| $114.85 | $179.86 | $303.81 | +304% | Bullish | |
| $170.99 | $292.99 | $531.68 | +559% | Bullish | |
| $301.18 | $605.64 | $1,218.47 | +12.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $13.51 | $44.49 | $51.94 | +0.00% |
| August 2026 | $37.86 | $44.65 | $54.07 | +0.37% |
| September 2026 | $39.36 | $46.91 | $57.74 | +5.05% |
| October 2026 | $40.26 | $48.39 | $60.34 | +3.16% |
| November 2026 | $39.88 | $48.27 | $60.81 | -0.25% |
| December 2026 | $41.03 | $49.97 | $63.55 | +3.52% |
Click any year to see its month-by-month DFTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, DFTX is projected to trade between $13.51 and $63.55, averaging $44.49 — a potential gain of 0% from today's $44.49. A consolidation phase looks the most probable path here.
Definium Therapeutics, Inc.'s 2027 outlook centres on $62.75, within a $48.95 to $85.67 range. That is up +41% on the projected 2026 average. That marks a +41% change versus current levels. Momentum favours further upside here.
By 2028, DFTX could reach as high as $96.77, with a base case around $67.75 and support toward $50.99 — roughly +52% from $44.49. Buyers look set to stay in control over this stretch.
Expect DFTX to range from $56.30 to $113.98 through 2029. The $77.07 average target implies a +73% move from current prices. That is up +14% on the projected 2028 average. Momentum favours further upside here.
The DFTX price prediction for 2030 points to an average of $84.15 (low $59.87, high $128.12) — a potential gain of +89% on today's $44.49. Buyers look set to stay in control over this stretch.
In 2031, DFTX is projected to trade between $66.16 and $148.75, averaging $95.27 — a potential gain of +114% from today's $44.49. That is up +13% on the projected 2030 average. Momentum favours further upside here.
Definium Therapeutics, Inc.'s 2032 outlook centres on $113.94, within a $77.35 to $181.95 range. That is up +20% on the projected 2031 average. That marks a +156% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, DFTX could reach as high as $227.48, with a base case around $139.59 and support toward $92.76 — roughly +214% from $44.49. Momentum favours further upside here.
Expect DFTX to range from $109.04 to $278.02 through 2034. The $167.46 average target implies a +276% move from current prices. That is up +20% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The DFTX price prediction for 2035 points to an average of $179.86 (low $114.85, high $303.81) — a potential gain of +304% on today's $44.49. Momentum favours further upside here.
In 2040, DFTX is projected to trade between $170.99 and $531.68, averaging $292.99 — a potential gain of +559% from today's $44.49. That is up +63% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Definium Therapeutics, Inc.'s 2050 outlook centres on $605.64, within a $301.18 to $1,218.47 range. That is up +107% on the projected 2040 average. That marks a +12.6x change versus current levels. Momentum favours further upside here.
Investing $1,000 in DFTX today (≈ 22.476961 DFTX) could be worth
$13,612.85
+$12,612.85 (+1261%) by 2050 · US Dollar
Based on the average projected DFTX price of $605.64 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DFTXwould be worth at today's price.
$1,000 invested in DFTX on Jul 30, 2025 (≈ 110.741974 DFTX) would be worth
$4,926.91
+$3,926.91 (+392.7%) today · 4.93× · US Dollar
Based on a DFTX entry price of $9.03 vs. today's $44.49.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $42.93 | $1,036.34 | +3.6% |
| 1 month ago | $47.04 | $945.79 | -5.4% |
| 3 months ago | $21.7 | $2,050.23 | +105.0% |
| 6 months ago | $16.88 | $2,635.66 | +163.6% |
| 1 year ago | $9.03 | $4,926.91 | +392.7% |
| All time (5.0y) ago | $46.05 | $966.12 | -3.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DFTX forecast.
Our base-case forecast reaches $89.00 around 2031.
Implied market cap at $89.00: $11.81B
Looking out over the multi-year forecast, Definium Therapeutics, Inc. shows a bullish trajectory with rising averages and growing ROIs across the horizon. The 2030 forecast carries an average of $79.92 with a min of $55.04, a max of $125.83 and an ROI of 86.7, reflecting accumulating upside as the pipeline progresses.
Beyond 2030, the projections extend into 2040 with an average of $276.27 and a max of $526.84 (ROI 545.5), and into 2050 with an average of $581.33 and a max of $1,239.20 (ROI 1258.2). The forecast also shows continued bullish sentiment through 2031–2035 and beyond, with rising annual averages and sizeable max values. These are estimates, not guarantees, and depend on development progress, regulatory outcomes, and market dynamics.
Tap a question to reveal the answer.
2030 min $55.04, avg $79.92, max $125.83; ROI 86.7; sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward with rising averages and ROIs (e.g., 2027 avg $61.38; ROI 43.4; 2050 avg $581.33; ROI 1258.2). These are estimates, not guarantees.
Yes, the forecast’s max by 2050 is $1,239.20.
Current price $42.80; market cap $5.68B.
30-day range low $33.19, high $55.19. Support $22.95; resistance $48.45. RSI(14) 60; SMA50 $31.37; SMA200 $19.71.
Definium Therapeutics, Inc. Community Discussion
0Share your Definium Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.